TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Hansa Biopharma AB ( (SE:HNSA) ) has shared an announcement.
Hansa Biopharma announced it will host a conference call to discuss its Q3 2025 interim results on October 30, 2025. The call, led by key executives, will cover the company’s financial performance and provide updates on its business and pipeline, reflecting its ongoing commitment to addressing serious medical needs in its field.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company leverages its proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation. Its portfolio includes imlifidase, an IgG antibody-cleaving enzyme therapy for kidney transplantation, and HNSA-5487, a next-generation IgG cleaving molecule.
Average Trading Volume: 587,510
Technical Sentiment Signal: Buy
Current Market Cap: SEK3.3B
For detailed information about HNSA stock, go to TipRanks’ Stock Analysis page.